Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement



Status:Terminated
Conditions:Hospital
Therapuetic Areas:Other
Healthy:No
Age Range:18 - 85
Updated:4/21/2016
Start Date:May 2007
End Date:August 2008

Use our guide to learn which trials are right for you!

KALAHARI-1: Kallikrein Antagonist (DX-88 [Ecallantide]) Effect on Blood Loss Associated With Heart Surgery Requiring Institution of Bypass

The primary objective of this study was to assess the efficacy and safety of 2 dose levels
of ecallantide versus placebo in reducing blood loss following cardiopulmonary bypass (CPB),
as measured by chest tube drainage during the first 12 hours postoperatively or until the
chest tube was removed, whichever came first, in patients undergoing primary coronary artery
bypass grafting (CABG), single valve repair, or single valve replacement.

The secondary objective was to compare the efficacy of all ecallantide-treated participants
(pooled high and low-doses) to placebo and to compare the high-dose to the low-dose
ecallantide group. Other secondary objectives were to evaluate pharmacokinetics and antibody
formation.

This was a Phase 2, randomized, double-blind, placebo-controlled, multi-center study
designed to assess the efficacy and safety of 2 dose levels of ecallantide compared to
placebo in reducing chest tube drainage in participants requiring CPB for primary CABG,
single valve repair, or single valve replacement. Participants were randomized in a 3:3:2
ratio to ecallantide high-dose regimen (maximum 91 mg), ecallantide low-dose regimen
(maximum 15 mg), or placebo. Randomization was stratified by surgical procedure so that
participants undergoing valve replacement would be evenly distributed across treatment arms.
Each participant received active drug or placebo administered in stages on the day of the
surgical procedure after induction of anesthesia (Day 1).

Participants were screened up to 14 days prior to surgery. Additional study procedures were
conducted on Day -1 or 1, peri-operatively, during the immediate postoperative period, and
on Days 2, 4, and 7 (or at the time of discharge from the hospital), and between Days 28 and
43 (follow-up).

Inclusion Criteria:

- Men and women ≥18 to ≤85 years of age

- Elective primary coronary artery bypass grafting (CABG), single valve repair, or
single valve replacement requiring CPB and full sternotomy

- No plan to use desmopressin acetate (DDAVP), atrial natriuretic hormone,
E-aminocaproic acid (EACA), tranexamic acid, or aprotinin during or postoperatively

- Female participants must be non-lactating and not pregnant

- If of childbearing potential, female participants must agree to use adequate
contraception for 1 month after receiving study drug

Exclusion Criteria:

- Concomitant surgery including but not limited to atrial septal defect repair,
multiple valve replacement, carotid endarterectomy, and combined CABG and valve
procedure

- Planned hypothermic CPB using temperatures less than 28 degrees Celsius

- Weight <55 kilograms (kg)

- Major end organ dysfunction, defined as:

- Cardiac:

- Left ventricular ejection fraction (LVEF) < 30% by left ventriculography,
echocardiogram, or catheterization (within 90 days prior to screening)

- Use of positive IV inotropic agents within 12 hours prior to surgery

- Preoperative use of intra-aortic balloon pump (IABP), left ventricular
assist device (LVAD), or extracorporeal membrane oxygenation (ECMO)

- Renal: Serum creatinine > 1.5 milligrams per deciliter (mg/dL)

- Hepatic: Aspartate aminotransferase (AST) or alanine transferase (ALT) > 2.5 x
upper limit normal

- Hematologic:

- Preoperative hematocrit (Hct) < 30%

- Platelet count < 100,000/mm^3

- Planned transfusion during surgical procedure

- History or family history of bleeding or clotting disorder (for example,
von Willebrand's Disease, idiopathic thrombocytopenia purpura (ITP),
thrombotic thrombocytopenia purpura (TTP), hematologic malignancy)

- Prothrombin time (PT) or activated partial thromboplastin time

- (aPTT) > 1.5 x normal range; if receiving unfractionated heparin
preoperatively, then abnormal preoperative PT/aPTT permitted

- Serious intercurrent illness or active infection

- Previous exposure to ecallantide

- Known allergy to ecallantide or any of its components, fentanyl, midazolam,
isoflurane, propofol, morphine, heparin, or protamine

- Autologous blood donation ≤ 30 days month prior to surgery

- Known substance abuse within 6 months prior to surgery

- Receipt of an investigational drug or device within 30 days prior to participation in
the current study

- Administration of:

- Eptifibatide < 12 hours prior to surgery

- Tirofiban hydrochloride (HCl) < 12 hours prior to surgery

- Enoxaparin sodium or other low- molecular-weight heparin < 24 hours prior to
surgery

- Clopidogrel <5 days prior to surgery

- Warfarin <5 days prior to surgery (Warfarin must be discontinued 5 days prior to
surgery and PT must be < 18 seconds)

- Ticlopidine <7 days prior to surgery

- Abciximab <24 hours prior to surgery
We found this trial at
15
sites
Houston, Texas 77225
?
mi
from
Houston, TX
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
617-667-7000
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
?
mi
from
Boston, MA
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
3400 Spruce St
Philadelphia, Pennsylvania 19104
 (215) 662-4000
Hospital of the University of Pennsylvania The Hospital of the University of Pennsylvania (HUP) is...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Aurora, Colorado 80045
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Birmingham, Alabama
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Boston, Massachusetts 02190
?
mi
from
Boston, MA
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Gastonia, North Carolina 28054
?
mi
from
Gastonia, NC
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Phoenix, Arizona
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials
750 East Adams Street
Syracuse, New York 13210
?
mi
from
Syracuse, NY
Click here to add this to my saved trials